Lyell Immunopharma develops CAR T-cell therapies specifically targeting solid tumors and hematologic malignancies, addressing the significant unmet medical need for more durable cancer treatments. Their technology focuses on generating enhanced CAR T cells that aim to improve patient outcomes in oncology.
Funding
$493M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
CAR T-cell therapies have shown promise in treating hematologic malignancies, but their efficacy in solid tumors remains limited due to challenges such as T-cell exhaustion and an immunosuppressive tumor microenvironment. Current CAR T-cell therapies often lack the durability needed to achieve long-term remission in patients with solid tumors.
Solution
Lyell Immunopharma is developing a novel approach to CAR T-cell therapy, specifically engineered to overcome the limitations observed in solid tumors and hematologic malignancies. Their technology aims to generate CAR T cells with enhanced functionality and persistence within the tumor microenvironment, leading to more durable anti-tumor responses. By focusing on addressing the underlying mechanisms of T-cell exhaustion and immune suppression, Lyell seeks to improve patient outcomes and expand the applicability of CAR T-cell therapy to a broader range of cancers. The company's pipeline includes programs targeting both solid tumors and hematologic malignancies with significant unmet medical need.
Target Audience
The primary target audience includes patients with solid tumors and hematologic malignancies who are in need of more effective and durable cancer treatments, as well as the physicians who treat them.
Features
- Technology designed to enhance CAR T-cell persistence and functionality in solid tumors.
- Pipeline targeting both solid tumors and hematologic malignancies.
- Focus on overcoming T-cell exhaustion and immunosuppression within the tumor microenvironment.
- Development of CAR T-cell therapies with the potential for more durable anti-tumor responses.
- Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate.